Compare NATL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | TARS |
|---|---|---|
| Founded | 2023 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2023 | 2020 |
| Metric | NATL | TARS |
|---|---|---|
| Price | $47.08 | $72.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $50.20 | ★ $99.80 |
| AVG Volume (30 Days) | ★ 750.1K | 648.3K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | 48.21 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $4,354,000,000.00 | $451,360,000.00 |
| Revenue This Year | $2.59 | $61.17 |
| Revenue Next Year | $4.15 | $26.47 |
| P/E Ratio | $40.70 | ★ N/A |
| Revenue Growth | 0.86 | ★ 146.71 |
| 52 Week Low | $33.31 | $53.89 |
| 52 Week High | $48.50 | $91.53 |
| Indicator | NATL | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 63.83 | 47.96 |
| Support Level | $45.40 | $60.95 |
| Resistance Level | $48.23 | $73.45 |
| Average True Range (ATR) | 0.48 | 3.16 |
| MACD | 0.17 | -0.24 |
| Stochastic Oscillator | 92.62 | 50.40 |
NCR Atleos Corp is a financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers, and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels, all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware, and its proprietary Allpoint network. Atleos manages its operations in the following segments: Self-Service Banking, which generates maximum revenue, Network, and Telecommunications and Technology. Geographically, it derives maximum revenue from the U.S.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.